Middle Cerebral Artery Acute Ischemic StrokePIMISUTTNCT04651010
Predictive Multimodal MRI Factors in Subacute Cerebral Artery Occlusiontreated by Thrombectomy (PIMISUTT)
A study testing Multimodal MRI in people with Middle Cerebral Artery Acute Ischemic Stroke, run by Poitiers University Hospital at 1 site in France.
Trial summary
Our study aims to measure metabolic and functional parameters of the infarcted territory by multimodal cerebral MRI in patients diagnosed with unilateral proximal occlusion of the middle cerebral artery and treated by thrombectomy in order to correlate those parameters to clinical outcome (evaluated by modified Rankin… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Middle Cerebral Artery Acute Ischemic Stroke
- What is being tested?
- Multimodal MRI
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 15 Nov 2021to 15 Aug 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged ≥ 18 years old
- Hospitalized at the Poitiers University Hospital
- Acute middle cerebral artery occlusion diagnosed by CT-scan or MRI
- NIHSS score ≥ 6 at admission
- To be treated by thrombectomy with or without fibrinolysis
- Written information delivered to the patient or his relatives concerning the study and its benefit and risk
Who cannot join
- Patients or relatives whom a loyal information about the study cannot be given
- Patient with cognitive impairments before MRI.
- Patients who cannot undergo MRI because of contraindications
- Patients too deteriorated to tolerate one hour long exam
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Predictive Multimodal MRI Factors in Subacute Cerebral Artery Occlusiontreated by Thrombectomy (PIMISUTT
Our study aims to measure metabolic and functional parameters of the infarcted territory by multimodal cerebral MRI in patients diagnosed with unilateral proximal occlusion of the middle cerebral artery and treated by thrombectomy in order to correlate those parameters to clinical outcome (evaluated by modified Rankin score) at 3 months.
We aim to find early radiologic predictive factors for favorable clinical outcome in this population of patients.
Read the detailed description
The treatment of acute ischemic stroke in the setting of intracranial large artery occlusion and especially middle cerebral artery occlusion (MCAO) with intravenous tissue plasminogen activator (IV-tPA) is associated with low rates of recanalization and high rates of neurological morbidity and functional dependence.
In the last few years, endovascular intervention (mechanical thrombectomy) has proven its safety and its efficacy on clinical outcome in patients diagnosed with MCAO and is now commonly recommended.
However, in this population of patients treated by thrombectomy, very few predictive factors, except for the post-procedural recanalization score (TICI), do exist to foresee the variability of clinical outcome.
Tissue viability of the infarcted territory can be approached by the measure of metabolic and morphological parameters (Na+, H+, phosphore, diffusion imaging) which can be non-invasively done by multimodal MRI, as suggest by recently published studies.
Our study plans to measure these parameters between 12 and 24 hours after acute ischemic stroke in patients with MCAO treated by thrombectomy in order to correlate those parameters to clinical outcome at 3 months (modifier Rankin Score).
- Being tested
- Multimodal MRI
- Keywords
- Ischemic stroke, acute middle cerebral artery occlusion, multimodal MRI, thrombectomy
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multimodal MRIOther
Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
| Study group | Role | What they receive |
|---|---|---|
| Multimodal MRI | Experimental | Not described Receives: Other: Multimodal MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between modified Rankin score at 3 months and multimodal MRI data
Measured: Month 3
Secondary outcomes (3)
Discharge National Institute of Health Stroke Score (NIHSS)
Measured: Month 3
National Institute of Health Stroke (NIHSS) score at 3 months
Measured: Month 3
Change in NIHSS score at 3 months compared to post-thrombectomy
Measured: Month 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2020
- Study start15 Nov 2021
- Primary completion15 Aug 2028 (estimated)
- Study completion15 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Middle Cerebral Artery Acute Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by Poitiers University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Poitiers University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04651010
- Sponsor's protocol ID
- PIMISUTT
- Other IDs
- 2020-A021118-31
- Acronym
- PIMISUTT
- Status last verified
- Oct 2026
- First submitted
- 25 Nov 2020
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive Multimodal MRI Factors in Subacute Cerebral Artery Occlusiontreated by Thrombectomy (PIMISUTT
- ClinicalTrials.gov ID
- NCT04651010
- Acronym / sponsor ID
- PIMISUTT / PIMISUTT
- Keywords
- Ischemic stroke, acute middle cerebral artery occlusion, multimodal MRI, thrombectomy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Poitiers University HospitalUniversity, hospital or other
- Study start
- 15 Nov 2021 (actual)
- Primary completion
- 15 Aug 2028 (estimated)
- Study completion
- 15 Aug 2028 (estimated)
- First posted
- 3 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our study aims to measure metabolic and functional parameters of the infarcted territory by multimodal cerebral MRI in patients diagnosed with unilateral proximal occlusion of the middle cerebral artery and treated by thrombectomy in order to correlate those parameters to clinical outcome (evaluated by modified Rankin score) at 3 months.
We aim to find early radiologic predictive factors for favorable clinical outcome in this population of patients.
Detailed description
The treatment of acute ischemic stroke in the setting of intracranial large artery occlusion and especially middle cerebral artery occlusion (MCAO) with intravenous tissue plasminogen activator (IV-tPA) is associated with low rates of recanalization and high rates of neurological morbidity and functional dependence.
In the last few years, endovascular intervention (mechanical thrombectomy) has proven its safety and its efficacy on clinical outcome in patients diagnosed with MCAO and is now commonly recommended.
However, in this population of patients treated by thrombectomy, very few predictive factors, except for the post-procedural recanalization score (TICI), do exist to foresee the variability of clinical outcome.
Tissue viability of the infarcted territory can be approached by the measure of metabolic and morphological parameters (Na+, H+, phosphore, diffusion imaging) which can be non-invasively done by multimodal MRI, as suggest by recently published studies.
Our study plans to measure these parameters between 12 and 24 hours after acute ischemic stroke in patients with MCAO treated by thrombectomy in order to correlate those parameters to clinical outcome at 3 months (modifier Rankin Score).
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Multimodal MRI | Experimental | Other: Multimodal MRI |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients aged ≥ 18 years old
- Hospitalized at the Poitiers University Hospital
- Acute middle cerebral artery occlusion diagnosed by CT-scan or MRI
- NIHSS score ≥ 6 at admission
- To be treated by thrombectomy with or without fibrinolysis
Key exclusion criteria (4 listed)
- Patients or relatives whom a loyal information about the study cannot be given
- Patient with cognitive impairments before MRI.
- Patients who cannot undergo MRI because of contraindications
- Patients too deteriorated to tolerate one hour long exam
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multimodal MRIMultimodal MRI will be realized between 12 and 24 hours after thrombectomy | Other | Multimodal MRI |
Primary outcome
Correlation between modified Rankin score at 3 months and multimodal MRI data
Time frame: Month 3
3 secondary outcomes
Discharge National Institute of Health Stroke Score (NIHSS)
Time frame: Month 3
National Institute of Health Stroke (NIHSS) score at 3 months
Time frame: Month 3
Change in NIHSS score at 3 months compared to post-thrombectomy
Time frame: Month 3
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Middle Cerebral Artery Acute Ischemic Stroke
Recruiting
Connectomic Alterations Following Acute Ischemic Stroke in the MCA Territory
Ischemic Stroke
Recruiting
Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery
Endovascular Therapy, Acute Ischemic Stroke
Enrolling by invitation
Roods vs PNF for Upper Limb Function in Acute MCA Stroke
Stroke, Middle Cerebral Artery Infarction
RecruitingObservational study
Translational Immunodiagnostics in Stroke (TrImS)
Acute Ischemic Stroke, Haemorrhagic Stroke
Not yet recruiting
Prognostic Value of Transcranial Doppler Ultrasound in the Clinical Evolution of Patients With Acute Ischemic Stroke. The TRADE-AIS Study
Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multimodal MRI in people with Middle Cerebral Artery Acute Ischemic Stroke, run by Poitiers University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Guillaume HERPE, Dr (05 49 44 33 89, guillaume.herpe@chu-poitiers.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between modified Rankin score at 3 months and multimodal MRI data (time frame: Month 3). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.